Navigation Links
The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients

- Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID and other Drugs in Newly Diagnosed Myeloma -

NORTH HOLLYWOOD, Calif., April 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma. High dose dexamethasone has been used as standard therapy for the treatment of myeloma alone and in combination with other drugs. However, interim findings from a large ongoing clinical trial of REVLIMID(R) plus dexamethasone in newly diagnosed patients, suggest lowering the "dex" dose may not only reduce side effects, but also may improve survival.

The trial, known as E4A03, is sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG). Based on these findings, ECOG has suspended further patient enrollment for this trial and has recommended that lower dose "dex" be considered for patients currently being treated on the high dose arm of the trial. Because of the public health implications, these findings are being made public immediately. The complete details will be presented at a cancer conference later this spring.

"Improved survival with low dose 'dex' and REVLIMID is an important finding because it further improves the outcome for an already successful treatment, while low dose dexamethasone is better tolerated by patients," said Brian G. M. Durie, M.D., chairman and co-founder of the International Myeloma Foundation. "We are recommending that physicians consider these findings when treating their patients across all stages of myeloma and that patients discuss these findings with their physicians."

Susie Novis, president and co-founder of
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:9/30/2014)... 2014  The orthopedic specialists at Midwest Orthopaedics ... orthopedic group by US News & World Report, are ... of free, public seminars to discuss partial and total ... come to see the knee physicians at Midwest Orthopaedics ... at Munster Specialty Surgery Center. The ...
(Date:9/30/2014)... PAUL, Minn. , Sept. 30, 2014 ... the United States abused prescription pain relievers ... include detoxification or maintenance treatment, which entails the use ... costs of these treatments are important when developing and ... by pharmacy benefit manager Prime Therapeutics LLC ...
(Date:9/30/2014)... 2014 Headquartered in Anaheim, California ... company comprised of several specialized partners focused on leveraging ... proven expertise of its team of professionals to improve ... line of more than 10 professional diagnostic tests for ... than 8 retail consumer tests is proud to announce ...
Breaking Medicine Technology:"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2
... Regado Biosciences, Inc., a privately held company ... control agents, announces one poster presentation and two ... Scientific Sessions meeting on November 14, 2011 during ... All three presentations highlight results from Regado,s pipeline ...
... Md., Nov. 14, 2011 Science, public health, ... Administration. Information in this document is designed for credentialed ... as of November 14, 2011. ... not contain any regulatory or enforcement actions due to ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4FDA News & Notes - Week of November 14, 2011 2FDA News & Notes - Week of November 14, 2011 3FDA News & Notes - Week of November 14, 2011 4
(Date:9/30/2014)... of Maryland-led research team has been awarded a ... of Health (NIH) to develop new imaging technologies ... understanding of how large networks of neurons in ... knowledge will help researchers identify the precise interactions ... like decision-making and speaking, and alterations in these ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... by certified nutrition specialist and best-selling author Mike Geary that ... and totally transform their body into a fat-burning machine in ... Michaels, prompting an investigative review. , “In our culture ... it can be hard to decipher what is really fact ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... Columbus, Ohio (PRWEB) September 30, 2014 ... and new viral strains emerging every day, it’s ... disinfecting system. The EnviroShield system is an ... and allows applications to surface normally missed with ... a spray nozzle that adds an electrostatic negative ...
(Date:9/30/2014)... SHELBY TOWNSHIP, Mich. (PRWEB) September 30, 2014 ... inventive chronic knee pain program of care ... patients. , His clinic—Johnson Chiropractic Neurology & ... focusing on the knee. It also addresses sources of ... as well as the “neurokinetic chain” from the brain ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... Virginia Tech,s College of Natural Resources and Environment, has ... Mycobacterium tuberculosis complex, a group of pathogens that ... been nearly two decades since a new organism was ... the early and mid 20th century. Tuberculosis is ...
... HealthDay Reporter , WEDNESDAY, Sept. 29 (HealthDay News) ... women finds that screening can lower the risk of dying ... study, done in Sweden, found that women who were screened ... women five times over a 10-year period would save one ...
... from The Commonwealth Fund provides recommendations for state and ... health insurance exchanges which are a key element of ... state-based exchanges, to be set up by states and ... with subsidized health insurance for small businesses and individuals ...
... that also have mutations in the BRCA gene appear to ... the same disease without the deleterious genetic mutation, according to ... The findings may offer a direction for study of ... cancer patients, as well as highlight the unique need for ...
... By Amanda Gardner HealthDay Reporter , ... that releases a progestin hormone may be an effective ... researchers report. By delaying a total hysterectomy, which ... allows women to remain fertile and possibly to have ...
... WEDNESDAY, Sept. 29 (HealthDay News) -- Driven by reports of ... positioners are dangerous and should not be used. The ... Drug Administration (FDA) and the U.S. Consumer Product Safety Commission ... babies under 4 months old suffocated in the last ...
Cached Medicine News:Health News:Virginia Tech professor discovers new TB pathogen 2Health News:Virginia Tech professor discovers new TB pathogen 3Health News:Mammograms Save Lives for Women in Their 40s, Study Says 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 3Health News:New health insurance exchanges should be independent, aim for level playing field 2Health News:New health insurance exchanges should be independent, aim for level playing field 3Health News:Study finds women with triple negative breast cancer and BRCA mutations have lower risk of recurrence 2Health News:Study finds women with triple negative breast cancer and BRCA mutations have lower risk of recurrence 3Health News: IUD Proposed to Treat Uterine Cancer 2Health News: IUD Proposed to Treat Uterine Cancer 3Health News:Infant Sleep Positioners Dangerous, U.S. Health Officials Warn 2Health News:Infant Sleep Positioners Dangerous, U.S. Health Officials Warn 3
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Implant System utilizes the same proven materials ... The SR™ Hand Implant System provides ... including minimal bone resection, surface replacement of ... retention and/or repositioning of the ligamentous soft ...
... can make simple motions such as gripping ... if not impossible. The Avanta Soft Skeletal ... effects of this disease. By incorporating ... design features these implants offer todays hand ...
Medicine Products: